InMode (INMD) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 Let me kick off this session with InMode. I'm Matt Taylor, the US medical supplies and devices analyst here at Jefferies. And from InMode, have Moshe Masrahi, the CEO joining us here virtually on the screen. And also Yair Melka, the CFO here next to me. So we have about a half hour for some moderated Q and A and maybe we'll go back and forth a little bit. Moshe, let me start high level with you and talk a little bit about just the company. I w ...

Mr. Pedro Escudero CEO and CIO DOMA, Perpetual Capital Management LLC Dear Mr. Escudero, This letter is in response to your letter dated May 9, 2025. YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated May 9, 2025. The letter can be viewed here The full text of ...

Summary of InMode (INMD) Conference Call - May 19, 2025 Company Overview - InMode is an Israeli-based company specializing in medical aesthetic equipment, particularly surgical equipment that penetrates the skin [2][3] - Established around 16 years ago, with R&D and manufacturing based in Israel [2] - The company went public in February 2019 at $7 per share and has since seen significant revenue growth [8] Financial Performance - Revenue reached approximately $495 million in 2023, up from $22 million in 2017 [5][6] - Experienced a 20% revenue decline in 2024 due to economic slowdown and increased interest rates [10] - Target for 2025 is to match 2024 revenue levels [10] Product and Technology - InMode's technology includes radio frequency-assisted lipolysis and bipolar Matrix RF (Morpheus) [4][6] - The company has diversified its product line to include applications for urinary incontinence, overactive bladder, and facial rejuvenation [6] - Currently has about 12 platforms in its product portfolio, selling in 90 countries [7] Market Dynamics - The U.S. market constitutes 50% of the business, with the rest coming from international markets [19] - The company faces stronger headwinds in the U.S. compared to international markets, with consumer confidence being a significant issue [22][27] - The first quarter is typically the slowest, with Q2 expected to be stronger [30] Operational Challenges - The ongoing conflict in Israel has posed challenges, but the company has managed to maintain operations [12][35] - Tariff exposure is estimated to impact gross margins by 2% to 3% due to most products being manufactured in Israel [38][39] Marketing and Sales Strategy - The company spends heavily on marketing and sales, with a focus on both B2B and B2C strategies [16][60] - Sales and marketing expenses account for 35% to 40% of revenue, while G&A and R&D expenses are relatively low at around 3% and 4%, respectively [59][60] Future Outlook - The company is optimistic about the recovery of the aesthetic procedure market, although it does not expect an immediate surge in demand [99] - Plans to continue product innovation, with new wellness platforms expected to launch later in 2025 [52] - The management is focused on international expansion, establishing subsidiaries in Argentina and Thailand [71][72] Capital Allocation - In the past 12 months, InMode has repurchased $412 million of its stock, totaling $508 million over two years [85][87] - The company is open to various capital allocation strategies, including further buybacks, M&A, and dividends, depending on market conditions [85][86] Key Risks - Economic slowdown and rising interest rates are significant risks affecting consumer spending on aesthetic procedures [10][22] - The company is closely monitoring inflation trends in both the U.S. and Europe [23] Conclusion - InMode remains a leader in the medical aesthetics market, with a strong focus on innovation and international growth despite current economic challenges [11][72]

YOKNEAM, Israel, May 7, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation ...

IRVINE, Calif., May 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District of California granted InMode's motion for default judgment against the DHGate sellers and awarded InMode a permanent injunction and damages for the defendants' sales and promotion of counterfeit goods.The Court's decision aims to protect safety and uphold InMode's trademark rights. The injunction includes freezing th ...

This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. The predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty. Efforts have been made to ensure the information's accuracy, but inadvertent errors may occur. Readers are advised to in ...

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Core Insights - Eyes On Park has introduced the Envision by InMode system, a revolutionary non-invasive technology for advanced dry eye treatment in New York City [1][4][17] - The system combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, improving patient outcomes significantly [3][16] Treatment Technology - The Envision system utilizes two complementary technologies: Forma-I radiofrequency technology and Lumecca-I intense pulsed light therapy [5][7] - Forma-I delivers bipolar radiofrequency energy to enhance blood circulation and stimulate natural healing processes, particularly effective for meibomian gland dysfunction [6][11] - Lumecca-I uses intense pulsed light to reduce inflammation and improve symptoms in patients with inflammatory dry eye and ocular rosacea [7][12] Treatment Benefits - Patients typically experience noticeable improvement after just one session, with optimal results achieved after a series of treatments [15][16] - The Envision system provides a non-invasive treatment option that requires no downtime, allowing patients to resume normal activities immediately [15][16] Personalized Care - Treatment plans are customized based on comprehensive diagnostic testing, including advanced K5M diagnostic scans, allowing for tailored approaches to each patient's specific needs [14][15] - The practice emphasizes that no two cases of dry eye disease are identical, leading to higher patient satisfaction through targeted treatment [15] Availability - The Envision by InMode system is now available at Eyes On Park, and patients can schedule consultations to determine the suitability of this advanced treatment [17][18]

INMODE PROFILE & STRATEGY APRIL 2025 SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "exp ...

InMode (INMD) Q1 2025 Earnings Call April 28, 2025 08:30 AM ET Company Participants Miri Segal - Founder & CEOMoshe Mizrahy - Chairman and Chief Executive OfficerYair Malca - CFOMatt Taylor - Managing DirectorCaitlin Cronin - DirectorSam Eiber - Vice President - Equity ResearchDane Reinhardt - Senior Equity Research Associate Conference Call Participants Matt Miksic - Equity Research AnalystDanielle Antalffy - AnalystMike Matson - Senior Equity Research Analyst Operator Good day and welcome to InMode's Firs ...